Evidence map›Paper›PMID 41269210›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.

Alexandra M Hoyt-Miggelbrink, Jessica Waibl Polania, Luke Wachsmuth, Selena Lorrey, Aditya Mohan, Andrew Hardigan, Emily Blandford, Emily Lerner, Daniel Wilkinson, Kelly M Hotchkiss and 5 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. CD8Cancer cell international · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alexandra M Hoyt-MiggelbrinkDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-1499-2269
Jessica Waibl PolaniaDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-5204-8191
Luke WachsmuthDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2995-2983
Selena LorreyDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-5567-2830
Aditya MohanDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7614-9387
Andrew HardiganDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-1770-2757
Emily BlandfordDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0009-0000-7440-3185
Emily LernerDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-1597-8581
Daniel WilkinsonDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-9619-6914
Kelly M HotchkissDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-9175-1579
Sarah CookDuke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-0516-9388
Saskia HemmersDepartment of Integrative Immunobiology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-5575-0509
Anoop PatelDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-7078-9535
Katayoun Ayasoufi *Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-3797-0823
Peter Fecci *Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2912-8695

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Cancer Research Institute (CRI) Arash Ferdowsi Lloyd Old STAR AwardNIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

purposeExhaustion represents a collection of programmed T-cell differentiation states and an important mode of T-cell dysfunction. T-cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor thymocyte selection-associated HMG box (TOX). Our understanding of factors regulating TOX expression and the transition from progenitor to terminal exhaustion, however, remains incomplete. EXPERIMENTAL

designSingle-cell RNA sequencing was used to evaluate the expression of TNF receptors on human and murine tumor-infiltrating CD8+ T cells. Flow cytometry was utilized to assess exhaustion markers and TNF receptors on CD8+ T cells. Bulk RNA sequencing was used to demonstrate the role of TNFR2 on the overall exhaustion profile. Finally, the effect of TNFR2 on the overall antitumor response was established using TNFR2-knockout (KO) mice and an antagonist.

resultsWe reveal that upregulation of TNFR2 coincides with the gain of phenotypic markers and functions reflective of terminal exhaustion. Loss of TNFR2 affords a novel population of T cells that expresses TIM3 but possesses diminished TOX levels and contains functional characteristics of both progenitor and terminally exhausted cells. TIM3+ TNFR2-KO T cells exhibit reduced exhaustion transcriptional programs and enhanced AP1 pathway signatures. Finally, TNFR2-KO mice demonstrate improved T cell-dependent control of tumor and chronic lymphocytic choriomeningitis infection, whereas pharmacologic antagonism of TNFR2 licenses responses to checkpoint blockade in multiple subcutaneous and intracranial tumor models.

conclusionsOur data place TNFR2 signaling as a potential upstream regulator of TOX expression in T cells and propose TNFR2 antagonism as a novel immunotherapeutic strategy.

Indexed as

CD8-Positive T-LymphocytesLymphocytic ChoriomeningitisNeoplasmsReceptors, Tumor Necrosis Factor, Type IIAnimalsCell Line, TumorHigh Mobility Group ProteinsHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMice, KnockoutUp-RegulationHigh Mobility Group ProteinsReceptors, Tumor Necrosis Factor, Type IITOX protein, human

Identifiers

PMID41269210
PMCPMC13056295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.